Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

VTVT vs MTNB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MTNB Captures Overall Composite Edge (54.6 HOLD vs 38.9 SELL), While VTVT Leads 4–1 on Growth & Valuation Pillars

MTNB Overall Winner 6-Pillar Tally: VTVT 4 – 1 MTNB (1 Tie) Matrix Metrics: VTVT 4 – 4 MTNB

As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) captures the overall head-to-head institutional edge over vTv Therapeutics Inc. (VTVT) on higher Unified Composite conviction (54.6/100 HOLD vs. 38.9/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality), while VTVT wins 4–1 across the 6-pillar growth and valuation breakdown. VTVT trades at $16.36 (N/M Forward P/E, -29.8% operating margin) versus MTNB at $0.81 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: MTNB earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. VTVT 38.9/100 SELL) and -7.20β · 147% Vol risk profile, whereas VTVT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VTVT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.4); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTVT vs MTNB
VTVT NASDAQ
vTv Therapeutics Inc. Class A Common Stock
Pharmaceutical Preparations
$16.36
+0.8% 1D
Market Cap $65.5M
TTM Revenue $37M
Forward P/E N/M
Beta / 30D Vol 1.51β · 55% Vol
Unified Composite Score
38.9 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.6%), weak momentum, RSI 17
RSI-14: 17.4 · SMA20: $22.02 · SMA50: $26.77
MTNB NYSE American Head-to-Head Winner
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.81
-10.98% 1D
Market Cap $979,904
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -7.20β · 147% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 33.0 · SMA20: $1.26 · SMA50: $1.47

6-Pillar Scorecard Institutional Category Breakdown (VTVT 4 – 1 MTNB)

Columns: Metric · VTVT · MTNB
1. Valuation Multiples VTVT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.8x N/M
2. Growth & Scale VTVT
Revenue Growth (YoY) +0.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $37M N/A
Market Cap $65.5M $979,904
3. Profitability & Quality MTNB
Gross Margin 20.8% N/A
Operating Margin -29.8% 0.0%
Net Profit Margin -20.8% 0.0%
Return on Equity (ROE) -10.9% -147.5%
4. Balance Sheet & Cash Flow VTVT
Cash Generation (TTM) -$11M EBITDA N/A
Cash Flow Margin -29.8% EBITDA Mgn N/A
Net Cash / Leverage $5.60 Book/Sh · -10.9% ROE $1.2M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat VTVT
OpEx & R&D Intensity 50.6% of Rev ($19M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTVT (4) vs MTNB (4)
Institutional Metric VTVT MTNB Criterion Row Edge
Market Capitalization
Scale
$65.5M $979,904 Larger Scale VTVT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -100.0% Higher Growth VTVT
Operating Margin (TTM)
Profitability
-29.8% 0.0% Higher Margin MTNB
Net Profit Margin
Profitability
-20.8% 0.0% Higher Margin MTNB
Return on Equity (ROE)
Capital Efficiency
-10.9% -147.5% Higher ROE VTVT
52-Week Range Position
Momentum
2% ($16–$44) 22% ($0–$3) Stronger Trend MTNB
Beta / 30D Volatility
Risk Regime
1.51β · 55% Vol -7.20β · 147% Vol Lower Realized Risk VTVT
Unified Institutional Score
Composite Signal
38.9 / 100 (SELL) 54.6 / 100 (HOLD) Higher Composite MTNB
Trailing 12M Revenue (USD)
Operating Scale
$37M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
20.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($5.60 Book/Sh · -10.9% ROE) N/A ($1.2M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTVT +5.61 pp
VTVT: -41.09% · MTNB: -46.7%
3M Horizon MTNB +358.29 pp
VTVT: -50.8% · MTNB: +307.49%
6M Horizon MTNB +74.85 pp
VTVT: -53.92% · MTNB: +20.93%
1Y Horizon MTNB +14.32 pp
VTVT: -45.67% · MTNB: -31.35%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTVT vs MTNB. Trailing 12-month operating profitability (VTVT -29.8% vs MTNB 0.0%) and valuation multiples (VTVT N/M vs MTNB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VTVT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$37M
Gross Margin20.8%
Op. Margin-29.8%
ROE / Fwd P/E-10.9% · N/M
MTNB ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-147.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTVT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MTNB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $65.5M market capitalization and -29.8% operating margin.
OpEx & R&D Reinvestment 50.6% of Rev ($19M)
90D Engineering Disclosures 0 Published
MTNB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTVT vs MTNB Key Questions & Quantitative Answers

As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) captures the overall head-to-head institutional edge over vTv Therapeutics Inc. (VTVT) on higher Unified Composite conviction (54.6/100 HOLD vs. 38.9/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality), while VTVT wins 4–1 across the 6-pillar growth and valuation breakdown. VTVT trades at $16.36 (N/M Forward P/E, -29.8% operating margin) versus MTNB at $0.81 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: MTNB earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. VTVT 38.9/100 SELL) and -7.20β · 147% Vol risk profile, whereas VTVT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VTVT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.4); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VTVT leads the Growth & Scale pillar: VTVT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $37M TTM revenue (20.8% gross margin, -29.8% operating margin), compared with MTNB at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VTVT generates $37M in USD-normalized revenue versus N/A for MTNB. In operating R&D and SG&A reinvestment, VTVT deploys 50.6% of Rev ($19M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTNB.

VTVT screens cheaper on headline valuation multiples. VTVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.8x EV/Revenue (-29.8% EBITDA margin), whereas MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTVT (-10.9% ROE) versus MTNB (-147.5% ROE) capital efficiency.

In options market volatility and institutional positioning, VTVT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.51β · 55% Vol realized risk). By comparison, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.